ClinicalTrials.gg
CompletedNCT00848081Updated Sep 14, 2010Results posted

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers

A Phase 3 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 31 sites in 2 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2010-09-14.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
12th of 26
318 · median 258
Started
2009
with 4 others
Phase 3
10 of 26
none open now
Registered
7th of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 12th largest by enrollment, is one of 5 that started in 2009, is one of 10 in phase 3, and was the 7th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (BPH) symptoms (such as urinary frequency, urgency, and a feeling that the bladder is not completely emptied after urination).

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

Keywords

  • Prostate
  • BPH
  • Benign Prostatic Hyperplasia
  • BPH-LUTS
  • LUTS
  • Phosphodiesterase Inhibitors
  • tadalafil
  • alpha blockers
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable on alpha blocker therapy for the treatment of BPH for at least 4 weeks prior to starting the study.
  • Have not taken the following treatments within the indicated duration and agree not to use at any time during the study:

    1. All other Benign Prostatic Hyperplasia therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication.
    2. Overactive Bladder therapy (including antimuscarinics) for at least 4 weeks prior to receiving study medication.
    3. Erectile Dysfunction therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication.
  • If taking finasteride or dutasteride, must have been taking treatment for at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • Currently receiving alpha-blocker therapy for the treatment of hypertension.
  • History of symptoms associated with orthostasis, including recurrent episodes of dizziness, lightheadedness, loss of consciousness, or syncope.
  • Treated with nitrates for any cardiac conditions.
  • Have had any of the following in the past 90 days: Heart attack, also known as a myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft surgery); Had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention).
  • Have problems with kidneys, liver, or nervous system
  • Have uncontrolled diabetes
  • Have prostate cancer, are being treated for cancer or have clinical evidence of prostate cancer (PSA greater than 10 ng/ml at the start of study).
  • Have had a stroke or a significant injury to brain or spinal cord.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
318 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Tadalafil

    Drug: Tadalafil

Interventions

  • 5 mg taken by mouth once daily for 12 weeks

    Also known as: LY450190, Cialis

  • DrugPlacebo

    By mouth once daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Number of Men With Treatment-emergent Dizziness

    The primary safety measure is the proportion (reported in numbers) of subjects experiencing treatment-emergent dizziness to include the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms of dizziness, dizziness postural, and procedural dizziness. Treatment-emergent dizziness is defined as any of the predefined terms of dizziness that is first reported or worsens in severity after baseline.

    Time frame: Baseline through 12 Weeks

Secondary outcomes

  1. Number of Participants With Positive Orthostatic Vital Signs Test; Shift From Any Pre-Randomization to Any Post-Randomization Visit

    A positive orthostatic test is defined as at least one of the following 4 criteria being met at any pre-randomization or post-randomization visit: (1) reduction in systolic blood pressure of \>= 20 mmHg from the supine to standing position;(2)reduction in diastolic blood pressure of \>=10 mmHg from the supine to standing position;(3)increase in heart rate of \>= 20 bpm from the supine to standing position; or (4)Unable to remain standing. A negative orthostatic test is defined as none of the above 4 criteria (1, 2, 3, or 4) being met at any pre-randomization or post-randomization visit.

    Time frame: Baseline through 12 Weeks

  2. International Prostate Symptom Score (IPSS) Change From Baseline

    Change from baseline to endpoint in IPSS Score. The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

    Time frame: Baseline, 12 Weeks

  3. Postvoid Residual Volume (PVR) Change From Baseline

    Change from baseline to endpoint in PVR volume. PVR is obtained by measuring with ultrasound the remaining urine in the bladder after urination.

    Time frame: Baseline, 12 Weeks

  4. Uroflowmetry (Qmax) Change From Baseline

    Change from baseline to endpoint in Qmax. Qmax is defined as the peak urine flow rate (measured in milliliters per second \[mL/second\] using standard calibrated flowmeter).

    Time frame: Baseline, 12 Weeks

07

Results

Posted Sep 14, 2010

Participant flow

Participant flow — Overall Study
MilestonePlaceboTadalafil
Started160158
Completed140140
Not completed2018
Withdrew: Adverse event67
Withdrew: Protocol violation85
Withdrew: Lost to follow-up10
Withdrew: Physician decision03
Withdrew: Withdrawal by subject53

Outcome measures

PrimaryNumber of Men With Treatment-emergent Dizziness

The primary safety measure is the proportion (reported in numbers) of subjects experiencing treatment-emergent dizziness to include the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms of dizziness, dizziness postural, and procedural dizziness. Treatment-emergent dizziness is defined as any of the predefined terms of dizziness that is first reported or worsens in severity after baseline.

Time frame:
Baseline through 12 Weeks
Reported as:
Number · Participants
Number of Men With Treatment-emergent Dizziness
ParticipantsPlaceboTadalafil
Number of Men With Treatment-emergent Dizziness911
Statistical analysis
  • Placebo vs Tadalafil · Fisher Exact · p = 0.403 (1-sided test)
SecondaryNumber of Participants With Positive Orthostatic Vital Signs Test; Shift From Any Pre-Randomization to Any Post-Randomization Visit

A positive orthostatic test is defined as at least one of the following 4 criteria being met at any pre-randomization or post-randomization visit: (1) reduction in systolic blood pressure of \>= 20 mmHg from the supine to standing position;(2)reduction in diastolic blood pressure of \>=10 mmHg from the supine to standing position;(3)increase in heart rate of \>= 20 bpm from the supine to standing position; or (4)Unable to remain standing. A negative orthostatic test is defined as none of the above 4 criteria (1, 2, 3, or 4) being met at any pre-randomization or post-randomization visit.

Time frame:
Baseline through 12 Weeks
Reported as:
Number · Participants
Number of Participants With Positive Orthostatic Vital Signs Test; Shift From Any Pre-Randomization to Any Post-Randomization Visit
ParticipantsPlaceboTadalafil
Positive Pre-Random. to Negative Post-Random.2215
Negative Pre-Random. to Positive Post-Random.2119
Positive Pre-Random. to Positive Post-Random.1416
Negative Pre-Random. to Negative Post-Random.101106
SecondaryInternational Prostate Symptom Score (IPSS) Change From Baseline

Change from baseline to endpoint in IPSS Score. The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

Time frame:
Baseline, 12 Weeks
Reported as:
Mean · units on a scale
International Prostate Symptom Score (IPSS) Change From Baseline
units on a scalePlaceboTadalafil
Baseline13.3 ± 6.5713.87 ± 7.15
Change from Baseline-1.49 ± 5.29-2.28 ± 5.65
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = 0.130 (p-value is on change from baseline)
SecondaryPostvoid Residual Volume (PVR) Change From Baseline

Change from baseline to endpoint in PVR volume. PVR is obtained by measuring with ultrasound the remaining urine in the bladder after urination.

Time frame:
Baseline, 12 Weeks
Reported as:
Mean · milliliters
Postvoid Residual Volume (PVR) Change From Baseline
millilitersPlaceboTadalafil
Baseline values70.7 ± 74.8780.3 ± 80.78
Change from Baseline-1.9 ± 82.86-8.1 ± 88.5
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.258 (p-value is on change from baseline)The p-value is from Type III sums of squares ANOVA on rank-transformed data.
SecondaryUroflowmetry (Qmax) Change From Baseline

Change from baseline to endpoint in Qmax. Qmax is defined as the peak urine flow rate (measured in milliliters per second \[mL/second\] using standard calibrated flowmeter).

Time frame:
Baseline, 12 Weeks
Reported as:
Mean · milliliters per second
Uroflowmetry (Qmax) Change From Baseline
milliliters per secondPlaceboTadalafil
Baseline12.8 ± 5.8811.8 ± 4.93
Change from Baseline0.6 ± 4.030.6 ± 3.67
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.828P-value is from Type III sums of squares ANOVA on rank-transformed data; p-value is on change from baseline.

Adverse events

Collected over Treatment Emergent Adverse Events were collected from randomization until the subject completed the study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/160 (1.9%)53/160 (33.1%)
Tadalafil—2/158 (1.3%)65/158 (41.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboTadalafil
Mallory-Weiss syndromeGastrointestinal disorders0/1601/158
FallInjury, poisoning and procedural complications1/1601/158
Tendon ruptureInjury, poisoning and procedural complications0/1601/158
Non-cardiac chest painGeneral disorders1/1600/158
Hip fractureInjury, poisoning and procedural complications1/1600/158
Lead dislodgementInjury, poisoning and procedural complications1/1600/158
Most frequent other events
Showing 10 of 122
Most frequent other events
EventPlaceboTadalafil
DizzinessNervous system disorders8/16010/158
DyspepsiaGastrointestinal disorders0/1608/158
DiarrhoeaGastrointestinal disorders2/1605/158
Gastrooesophageal reflux diseaseGastrointestinal disorders1/1604/158
Back painMusculoskeletal and connective tissue disorders2/1604/158
NauseaGastrointestinal disorders2/1603/158
FatigueGeneral disorders1/1603/158
Upper respiratory tract infectionInfections and infestations3/1600/158
ColonoscopyInvestigations3/1600/158
HeadacheNervous system disorders3/1602/158

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboTadalafilTotal
Mean67.35 ± 9.1367.41 ± 9.1167.38 ± 9.10
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTadalafilTotal
Female000
Male160158318
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTadalafilTotal
Hispanic or Latino182038
Not Hispanic or Latino142138280
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTadalafilTotal
American Indian or Alaska Native101
Asian112
Native Hawaiian or Other Pacific Islander011
Black or African American141731
White144137281
More than one race022
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)PlaceboTadalafilTotal
United States157148305
Puerto Rico31013
08

Study locations

31 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Huntsville, Alabama 35801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Anchorage, Alaska 99508, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Anaheim, California 92801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Los Angeles, California 90017, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paramount, California 90723, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Diego, California 92120, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vacaville, California 95688, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Melbourne, Florida 32901, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orlando, Florida 32803, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pembroke Pines, Florida 33024, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. Petersburg, Florida 33710, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Palm Beach, Florida 33407, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 46254, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. Clair Shores, Michigan 48081, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Missoula, Montana 59802, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albuquerque, New Mexico 87109, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bayshore, New York 11706, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Garden City, New York 11530, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New York, New York 10016, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poughkeepsie, New York 12601, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Concord, North Carolina 28025, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salisbury, North Carolina 28144, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winston-Salem, North Carolina 27103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Edmond, Oklahoma 73034, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75231, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salt Lake City, Utah 84102, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Menomonee Falls, Wisconsin 53051, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bayamon, 00961-7049, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00921-3201, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santurce, 00907, Puerto Rico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2009
First posted
Feb 20, 2009
Start
Mar 2009
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Sep 14, 2010
Last update
Sep 14, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00848081
First posted
Feb 20, 2009
Start date
Mar 2009
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Sep 14, 2010
Last update
Sep 14, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM- 5 PM Eastern time (UTC/GMT -5 hourse, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion